Increased survival time in brain glioblastomas by a radioneuroendocrine strategy with radiotherapy plus melatonin compared to radiotherapy alone

Oncology (Switzerland)

Volumn 53, Issue 1, 1996, Pages 43-46

  Lissoni, Paolo ^a   Meregalli, Sofia ^a   Nosetto, Luca ^a   Barni, Sandro ^a   Tancini, Gabriele ^a   Fossati, Vittorio ^b   Maestroni, George ^c  

^a SAN GERARDO HOSPITAL   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c INSTITUTE OF PATHOLOGY   (Switzerland)

Author keywords

Brain tumors; Glioblastoma; Melatonin; Radiotherapy

Indexed keywords

MELATONIN; OPIATE PEPTIDE; PINEAL BODY HORMONE; STEROID;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BRAIN TUMOR; CANCER GROWTH; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GLIOBLASTOMA; HUMAN; INFECTION COMPLICATION; MALE; NEUROENDOCRINE SYSTEM; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; SURVIVAL TIME; TUMOR GROWTH;

ADULT; AGED; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MELATONIN; MIDDLE AGED; SURVIVAL ANALYSIS;

EID: 0030025155     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000227533     Document Type: Article

References (17)

1. Decker DA, Kinzie J, Evans R, Hakam AZ, AI-Sarraf M: Pilot study of combinant 5-fluoro-uracil, n.s-diaminodichloroplatinum II, and radiation therapy for grade III and IV astrocytomas. Am J Clin Oncol 1987;10:444-449.
2. Grunberg SM, Bertram JH, McDermed JE, Apuzzo MLJ: Treatment of astrocytomas with a 5-day cisplatin infusion. Cancer Drug Deliv 1987;4:47-52.
3. Koff WC, Dunegan MA: Modulation of macrophage-mediated tumoricidal activity by neuropeptides and neurohormones. J Immunol 1985;135:350-354.
4. Lissoni P, Tisi E, Brivio F, Ardizzoia A, Crispino S, Barni S, Tancini G, Conti A, Maestroni GJM: Modulation of interleukin-2-induced macrophage activation in cancer patients by the pineal hormone melatonin. J Biol Regul Homeost Agents 1991;5:154-156.
5. Westphal M, Li CH: Beta-endorphin: Characterization of binding sites specific for the human hormone in human glioblastoma SF 126 cells. Proc Natl Acad Sci USA 1984;81:2921-2924.
6. Krabtrce BL: Review of naltrexone, a long-acting opioid antagonist. Clin Pharmacol 1984;3: 237-281.
7. Fraschini F, Esposti D, Esposti D, Lissoni P, Lucini V, Cattaneo G: Clinical and experimental data on the relationship between pineal endocrine function and the opioid system. Adv Pineal Res 1987;2:171-180.
8. Lissoni P, Mercgalli S, Fossati V, Barni S, Tancini G, Berigozzi P, Frigerio F: Radioendocrine therapy of brain tumors with the long-acting opioid antagonist naltrexone in association with radiotherapy. Tumori 1993;79:198-201.
9. Wurtman RJ, Moskowitz MA: The pineal organ. N Engl J Med 1977,296:1329-1348.
10. Macstroni GJM, Conti A, Pierpaoli W: Role of the pineal gland in immunity. Immunology 1988;63:465-469.
11. Regelson W, Pierpaoli W: Melatonin: A rediscovered antitumor hormone? Cancer Invest 1987;5:379-385.
12. Lissom P, Barni S, Ardizzoia A, Tancini G Conti A, Macstroni GJM: A randomized stud; with the pineal hormone melatonin versus sup portive care alone in patients with brain metas tascs due to solid neoplasms. Cancer 1994;73 699-701.
13. Zulch DJ: Principle of the new World Hcaltl Organization (WHO) classification of brain tu mors. Neuroradiology 1980;19:59-66.
14. Macstroni GJM: The immunoneuroendocrim role of melatonin. J Pineal Res 1993;14:1-10.
15. Barry MA, Behnke CA, Eastman A: Activatior of programmed cell death (apoptosis) by cispla tin, other anticancer drugs, toxins and hyper thermia. Biochem Pharmacol 1990,40:2353-2358.
16. Grimm EA, Mazumder A, Zhang HZ, Rosen berg SA: Lymphokine-activated killer cell phenomenon. J Exp Med 1982; 155:1823-1841.
17. Kasid A, Bell GI, Director EP: Effects of transforming growth factor-p on human lymphokine-activated killer cell precursors: Autocriw inhibition of celllar proliferation and differentiation to immune killer cells. J Immunol 1988 141:690-695.